The Zhitong Finance App learned that on May 9, MSD (MRK.US) announced that the PD-1 inhibitor Keytruda (pabolizumab) combined chemotherapy (with or without radiotherapy) as adjuvant treatment for newly diagnosed and surgically treated high-risk endometrial cancer patients did not reach the main end point of disease-free survival (DFS). In the US, Keytruda has been approved for two indications for endometrial cancer treatment.
Keytruda has a comprehensive clinical development plan for endometrial cancer treatment, including the NRG-GY018/KEYNOTE-868 trial, which evaluated Keytruda in combination with standardized therapy (carboplatin and paclitaxel), and then Keytruda as a single agent to treat patients with advanced or recurrent endometrial cancer. The US FDA has given priority review to MSD's Supplemental Biologics License Application (SBLA) based on this study, and will make an approval decision with June 21, 2024.